期刊名称：EXPERT REVIEW OF ANTICANCER THERAPY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Aims & Scope
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Commentary - a personal view on the most effective or promising strategies
Five-year view - a clear perspective of future prospects within a realistic time scale
Key issues - an executive summary cutting to the author's most critical points
Instructions to Authors
Therapy Author Guidelines
Contents
Audience
Commissioning policy
Hybrid open access
Article types
Reviews
Research Articles
Case Reports
Perspectives
Special reports
Editorials
Priority paper evaluations
Conference reports
Key formatting points
Manuscript preparation
Spacing & headings
Spelling
Abbreviations
References
Format
Examples
Reference annotations
Figures/Tables/Boxes
Color printing charge
Chemical structures
Electronic figure files
Copyright
Submission
Peer review
R evision
Conflicts of interest policy
Financial disclosure
Author disclosure form
Ethics Committee approval
Contact
Editorial enquiries
Reprint/Sales enquiries
Future Medicine is part of the Future Science Group, an expanding group of independent
companies active in the field of scientific information and endeavor
Audience
The audience for Therapy consists of clinicians, research scientists, decision-makers and a range of
professionals in the healthcare community. Authors should bear in mind the multidisciplinary status
of the readership when writing the article.
Commissioning policy
We accept unsolicited manuscripts for publication in all Future Drugs journals. If you are interested in
submitting an article, please contact the Commissioning Editor of the relevant journal with a brief
proposal and article outline in the first instance.
We also have an active commissioning program whereby the Commissioning Editor, under the advice
of the Editorial Advisory Board, solicits articles for publication by Future Drugs.
Hybrid open access
Therapy is committed to the sharing of original research findings to all relevant parties free of charge
through its hybrid open-access program of publishing.
The journal represents an opportunity for medical researchers worldwide to submit original research
studies for publication, currently free of page charges or publication fees, for dissemination on a
hybrid open-access basis, whereby open-access publication of original research papers (plus a
selection of additional content) will be supported by high added value content - reviews, drug
profiles, which can be paid for by subscription or on a pay-per-view basis.
Articles included in the hybrid open-access model include: Editorials, News, Research Articles, Case
Reports, Special Reports, Perspectives, Conference Scenes, Priority Paper Evaluations and Clinical Trial
Reports.
Article types
Reviews
Word limit: 8000 words (excluding Abstract, Executive Summary, References and Figure/Table
legends)
Required sections: Abstract, Keywords, Conclusions, Future Perspective, Executive summary,
References, Reference Annotations
These articles aim to summarize current therapeutic practice, highlighting recent significant advances
and ongoing challenges and unmet needs. An evaluation of the pharmacoeconomic situation is
recommended where relevant. The final structure of the review will, of course, depend on the
title/focus.
Research Articles
Word limit: 5000 words (excluding Abstract, Executive Summary, References and Figure/Table
legends)
Required sections: Structured Abstract, Keywords, Background, Aim, Materials & Methods, Results,
Discussion/Conclusions, Future Perspective, Executive summary, References, Reference Annotations
These articles present an opportunity to researchers to present findings from their clinical studies for
publication under Therapy’s hybrid open access model. Research articles published in Therapy will be
available to download free of charge to all.
Structured abstracts should include the following:
Background; Aim; Materials & Methods; Results; Discussion/Conclusion
Case Reports
Word limit: 1500?000 words (excluding Abstract, Executive Summary, References and Figure/Table
legends)
Required sections: Structured Abstract, Keywords, Background, Aim, Materials & Methods, Results,
Discussion/Conclusions, Future Perspective, Executive summary, References, Reference Annotations
Case Reports present data on the treatment of a small group of patients (up to nine patients)
presenting with unique or rare symptoms. Case Reports examine the case and provide information
regarding the treatment approach used, indicating the reasoning behind the treatment and
outcomes.
Structured abstracts should include the following:
Background; Aim; Materials & Methods; Results; Discussion/Conclusion
Perspectives
Word limit: 3000 words (excluding Abstract, Executive summary, References and Figure/Table
legends)
Required sections: Abstract, Keywords, Conclusions, Future Perspective, Executive summary,
References, Reference Annotations
These articles have the same basic structure and length as review articles, however they should be
more speculative and very forward looking, even visionary. They offer the author the opportunity to
present criticism or address controversy. Authors of perspectives are encouraged to be highly
opinionated. The intention is very much that these articles should represent a personal perspective.
Referees will be briefed to review these articles for quality and relevance of argument only. They will
not necessarily be expected to agree with the authors?sentiments.
Special Reports
Word limit: 1500?000 words (excluding Abstract, Executive summary, References and Figure/Table
legends)
Required sections: Abstract, Keywords, Conclusions, Future Perspective, Executive summary,
References, Reference Annotations
These articles are short review-style articles that summarize a particular niche area, be it a specific
technique or therapeutic method, particularly focusing on the authors personal experience in this
area.
Editorials
Word limit: 1000?500 words
Required sections: Photo (headshot) of authors (Please try to avoid the use of figures and tables in
editorials)
These are short articles on issues of topical importance. We encourage our editorial writers to express
their opinions, giving the author the opportunity to present criticism or address controversy. The
intention is very much that the article should offer a personal perspective on a topic of recent interest.
Key paper evaluations
Word limit: 1500 words
Required sections: Abstract, Keywords, Conclusions, Executive Summary, References, Reference
Annotations (NB. The paper being evaluated should be listed in the bibliography as reference 1)
These articles review significant, recently published primary research articles carefully selected and
assessed by specialists in the field. The primary research detailed in the chosen paper is discussed
with the aim of keeping readers informed of the most promising discoveries/breakthroughs relevant
to the subject of the journal through review and comment from experts.
Key Paper Evaluations are intended to extend and expand on the information presented, putting it in
context and explaining why it is of importance.
The ideal article will provide both a critical evaluation and the author’s opinion on the quality and
novelty of the information disclosed.
Meeting Reports
Word limit: 1500 words
Required sections: Please provide the name, date and location of the conference being reported
These articles aim to summarize the most important research presented at a recent conference in the
subject area of the journal.
It is not usually feasible to attempt comprehensive coverage of the conference, as presentations are
frequently too numerous for each to be done justice. The author should focus on those presentations
that are most topical, interesting or thought-provoking.
Key formatting points
Please ensure your paper concurs with the following article format:
Title: concise, not more than 120 characters.
Author(s) names & affiliations: including full name, address, phone & fax numbers and e-mail.
Abstract/Summary: approximately 120 words.
Keywords: approximately 5?0 keywords for the review.
Body of the article
Conclusion: expert analysis of the data presented in the review.
Future Perspective: a speculative viewpoint on how the field will evolve in 5?0 years time.
Executive summary: bulleted summary points that illustrate the main topics or conclusions made
under each of the main headings of the article.
References:
?Should be numerically listed in the reference section in the order that they occur in the text.
References should appear as a number i.e., [1,2] in the text.
?If websites or patents are included, please use a separate numbering system, i.e., start
numbering website references at [101] and patents at [201] to allow the reader to
distinguish between websites/patents and primary literature references both in the text and
in the bibliography.
?Any references that are cited in figures/tables/boxes that do not appear in the text should
be listed at the end of the reference list in the order they occur.
Reference annotations: please highlight 6? references that are of particular significance to the
subject under review as ? of interest?or ?* of considerable interest?and provide a brief (1? line)
synopsis.
Figures/Tables/Boxes: Summary figures/tables/boxes are very useful, and we encourage their use in
reviews/perspectives/special reports. The author should include illustrations and tables to condense
and illustrate the information they wish to convey. Commentary that augments an article and could
be viewed as ‘stand-alone?should be included in a separate box. An example would be a summary
of a particular trial or trial series, a case study summary or a series of terms explained.
If any of the figures used in the manuscript require permission from the original publisher, it is the
author’s responsibility to obtain this. Figures must be in an editable format.
Manuscript preparation
Spacing & headings
Please use double line spacing throughout the manuscript. No more than four levels of subheading
should be used to divide the text and should be clearly designated.
Abbreviations
Abbreviations should be defined on their first appearance, and in any table and figure footnotes.
A separate list of abbreviations is useful to our production department but not a strict requirement.
Spelling
US-preferred spelling will be used in the finished publication.
References
Authors should focus on recent papers and papers older than 5 years should not be included except
for an over-riding purpose.
References should be denoted numerically and in sequence in the text, using Arabic numerals placed
in square brackets, i.e., [12].
If websites or patents are included, please use a separate numbering system for them, i.e., start
numbering website references at [101] and patents at [201] to allow the reader to distinguish
between websites/patents and primary literature references both in the text and in the bibliography.
The Future Drugs EndNote style for references is available to download from the Future Drugs
website (compatible with Mac EndNote 9).
Format
?Author’s names should appear without full stops in their initials
?Quote first six authors?names. If there are more than six, then quote first three et al
?A colon follows authors?names.
?Journal name should be in italics and abbreviated to standard format
?Volume number followed by comma, not bold
?Page number range separated by a hyphen with no spaces, followed by the year in brackets,
and then a full stop
Examples
Journal example:
Fantl JA, Cardozo L, McClish DK et al.: Estrogen therapy in the management of urinary incontinence
in postmenopausal women: a meta-analysis. Obstet. Gynecol. 83(1), 12?8 (1994).
Book example:
De Groat WC, Booth AM, Yoshimura N: Neurophysiology of micturition and its modification in
animal models of human disease. In: The Autonomic Nervous System (Volume 6). Andrews WR (Ed.),
Harwood Academic Publishers, London, UK, 227?89 (1993).
Meeting abstract example:
Smith AB, Jones CD. Recent progress in the pharmacotherapy of diseases of the lower urinary tract.
Presented at: 13th International Symposium on Medicinal Chemistry. Atlanta, GA, USA, 28
November? December 1994.
Patent example:
Merck Frosst Canada, Inc. WO9714691 (1997).
(Use the following formats for patent numbers issued by the World, US and European patent offices,
respectively: WO1234567, US1234567, EP-123456-A).
Reference annotations
Papers or of particular interest should be identified using one or two asterisk symbols:
?= of interest
?** = of considerable interest
Each of the chosen references should be annotated with a brief sentence explaining why the
reference is considered to be of interest/particular interest.
Figures/Tables/Boxes
Figures/Tables/Boxes should be numbered consecutively according to the order in which they have
been first cited in the text. Define in the legend all abbreviations that are used in the figure.
Figures/Tables/Boxes should be provided in separate files to the text. It is unnecessary to incorporate
the figures into the body of the manuscript.
Color figure charge
The final print-only copy of the journal will be printed in black and white. Should an author wish to
have colour figures in the complimentary hard copy of the journal, there is a small charge (calculated
per color page required). We aim to keep our color charge to a minimum and we are happy to work
with authors to come to a suitable arrangement.
This charge does not apply to the online (including PDF) version of articles, where all figures appear
in color at no charge.
Chemical structures
If possible, please submit structures drawn in ISIS/Draw or ChemDraw format. However, chemical
structures can be redrawn in-house. Please use the following conventions:
?Always indicate stereochemistry where necessary ?use the wedge and hash bond
convention for chiral centers and mark cis/trans bonds as such
?Draw small peptides (up to five amino acids) in full; use amino acid abbreviations (Gly, Val,
Leu, etc.) for larger peptides
?Refer to each structure with a number in the text; submit a separate file (i.e., not pasted
throughout the text) containing these numbered structures in the original chemical drawing
package that you used and as a hard copy.
Electronic figure files
Please submit any other illustrations/schemes in an electronic format such as Illustrator, CorelDraw,
PowerPoint, Excel or as PC-compatible postscripted/encapsulated postscripted (.ps/.eps) files.
Otherwise, please ensure camera-ready copy is of high resolution.
Copyright
If a figure has been published previously (even if you were the author), acknowledge the original
source and submit written permission from the copyright holder to reproduce the material.
As the author of your manuscript, you are responsible for obtaining permissions to use material
owned by others. Since the permission-seeking process can be remarkably time-consuming, it is wise
to begin writing for permission as soon as possible. Please send us photocopies of letters or forms
granting you permission for the use of copyrighted material so that we can see that any special
requirements with regard to wording and placement of credits are fulfilled. Keep the originals for
your files. If payment is required for use of the figure, this should be covered by the author.
Submission
Please ensure that manuscripts are submitted on or before the agreed deadline. If a manuscript
requires authorization by your organization before submission, please remember to take this into
account when working towards these deadlines.
If possible, please submit manuscripts in MS Word v. 6? and above. However, we can convert most
word-processing packages. Submission should be made by e-mail in the first instance.
Peer review
Once the manuscript has been received in-house, it will be peer-reviewed (this usually takes 2?
weeks). Please provide a list of suitable peer reviewers with your initial submission.
Revision
After peer review is complete, a further 2 weeks is allowed for any revisions (suggested by the
referee/Editor) to be made.
Conflicts of interest policy
It is the responsibility of the author(s) to disclose any affiliation with any organization with a financial
interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as
consultancies, employment, expert testimony, honoraria, speakers' bureaus, retainers, stock options
or ownership) that may affect the conduct or reporting of the work submitted. If uncertain as to
what might be considered a potential conflict of interest, authors should err on the side of full
disclosure.
Authors will be asked to certify that the manuscript represents valid work and that neither this
manuscript nor one with substantially similar content under my authorship has been published or is
being considered for publication elsewhere, except as described in an attachment, and copies of
closely related manuscripts are provided.
External peer reviewers must disclose any conflicts of interest that could bias their opinions of the
manuscript, and they should disqualify themselves from reviewing specific manuscripts if they believe
it appropriate. Should any such conflict of interest be declared, the journal Editor will judge whether
the reviewer's comments should be recognized or will interpret the reviewer's comments in the
context of any such declaration.
Details of relevant conflicts of interests (or the lack of) must be declared in the 'Disclosure' section of
the manuscript for all listed authors.
Future Medicine expects manuscripts to conform to the Uniform Requirements for Manuscripts
Submitted to Biomedical Journals (the Vancouver style; N. Engl. J. Med. 336, 309?15 [1997] or
www.icmje.org).
Financial disclosure
Authors are required to declare any financial interests relating to their manuscript or to confirm that
they have no such interest.
Authors must certify that all financial and material support for the research and work are clearly
identified in the manuscript.
Authors must certify that all affiliations with or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject matter or materials discussed in their
manuscript have been disclosed.
Please note examples of financial involvement include: employment, consultancies, honoraria, stock
ownership or options, expert testimony, grants or patents received or pending and royalties. This is
list is not exclusive of other forms of financial involvement.
Author disclosure form
The form at the end of this document should be completed by the authors and submitted with the
1st draft of the article.
Ethics Committee approval
Ethics Committee approval should be obtained for all research articles prior to article submission.
Please state the committee from which approval was obtained and submit a copy of your approval
certification with the first draft of your manuscript.
Contact Details
Editorial Enquiries
Kelly McCauley
Editor, Therapy
Future Medicine,
Unitec House,
Finchley Central,
London N3 1QB
UK
Tel: +44 (0)20 8349 2033
Fax: +44 (0)20 8343 2313
Email: k.mccauley@futuremedicine.com
www.future-science-group.com
Reprint/Sales enquires
Joanne Walker
Business Development Manager
Future Science Group,
Unitec House,
Finchley Central,
London N3 1QB
UK
Tel: +44 (0)20 8349 2033
Fax: +44 (0)20 8343 2313
Email: j.walker@futuremedicine.com
www.future-science-group.com
Editorial Board
Editorial Staff
Senior Editors: Kelly McCauley
Morag Robertson
Managing Editor: Kelly McCauley
Commissioning Editor: Sara Guy
Assistant Commissioning Editors: Louise Muttram
Lucy Tipton
Managing Production Editor: Barbara Ward
Production Editor: Arianwen Morris
Assistant Production Editors: Joanna Bolesworth
Cheryl Lenny
Jennifer O'Callaghan
|
